



## **Aptuit, Inc.** **Receives *CEO Cancer Gold Standard*<sup>™</sup> accreditation**

CARY, NC (September 15, 2009) – Aptuit, Inc. has received CEO Cancer Gold Standard<sup>™</sup> accreditation, recognizing the organization’s commitment to the health of their employees and family members by certifying their efforts to meet an exceptionally high standard of cancer prevention, screening and care guidelines.

William C. Weldon, chairman and chief executive officer of Johnson & Johnson chairs the CEO Roundtable on Cancer, the nonprofit organization of cancer-fighting CEOs who created the CEO Cancer Gold Standard<sup>™</sup>, in collaboration with the National Cancer Institute, many of its designated cancer centers, the American Cancer Society, CDC and leading health professionals.

“Our Gold Standard certification acknowledges the personal leadership of Chairman and CEO Tim Tyson and recognizes that Aptuit’s efforts to improve health begin with the company’s own employees and their family members,” said Weldon.

The CEO Cancer Gold Standard<sup>™</sup>, calls for companies to evaluate their benefits and culture and take extensive, concrete actions in five key areas of health and wellness to fight cancer in the workplace. To earn Gold Standard accreditation, a company must establish programs to reduce cancer risk by discouraging tobacco use and encouraging physical activity, healthy diet and nutrition; detect cancer at its earliest stages; and provide access to quality care, including the availability of clinical trials.

Aptuit’s commitment to cancer prevention and employee health and wellness was inspired by Chairman and CEO, Timothy C. Tyson. Prior to joining Aptuit in 2008, Tyson served as COO, President and CEO of Valeant Pharmaceuticals International, a company he also helped lead to CEO Cancer Gold Standard accreditation.

Other organizations joining Aptuit in championing this workplace-based effort to eliminate cancer as a public health threat include: American Cancer Society, American Legacy Foundation, AstraZeneca, C-Change, CIGNA, Dana-Farber Cancer Institute, Duke Medicine, Edelman, Enzon Pharmaceuticals, Fox Chase Cancer Center, GHI, an EmblemHealth company,

GlaxoSmithKline, Hogan & Hartson, Independence Blue Cross, Jenner & Block, Johnson & Johnson, The Lance Armstrong Foundation, MD Anderson Cancer Center, Millennium: The Takeda Oncology Company, Minot State University, H. Lee Moffitt Cancer Center and Research Institute, The National Cancer Institute (NCI), Novartis, The Oncology Nursing Society, OSI Pharmaceuticals, Pfizer, PhRMA, PPD, Quintiles Transnational, sanofi-aventis, SAS Institute, The University of North Dakota, US Oncology, Valeant Pharmaceuticals, Vanderbilt-Ingram Cancer Center, Virtua Health and The Wistar Institute.

#### About Aptuit

Aptuit, Inc. is a global company focused on streamlining and supporting the drug development process for biotechnology and pharmaceutical innovators. The company was founded by a group of industry experts with extensive market experience who have a track record of building a similar, highly successful company through acquisitions and investment. Aptuit provides a comprehensive suite of product development services and competencies to more than 800 biotechnology and large, fully integrated pharmaceutical innovators worldwide. Aptuit's mission is to engineer a better drug development process, and is partnered with Welsh, Carson, Anderson & Stowe, one of the world's largest private equity investors. For more information about Aptuit, please visit [www.apuit.com](http://www.apuit.com).